Business Insider: Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults Florida Today: IBS Awareness Month: What to know about symptoms and treatments April is IBS Awareness Month. Learn about irritable bowel syndrome symptoms, diagnosis, and treatment options. Healthline: Some IBS Treatments May Be Linked to Slightly Higher Risk of Early Death Some IBS Treatments May Be Linked to Slightly Higher Risk of Early Death Yahoo: IBS is more common than many realize.

Understanding the Context

Here's how these treatments can help. IBS is more common than many realize. Here's how these treatments can help. Research indicates that antidepressant use in IBS is linked to a 35% higher risk of all-cause mortality, highlighting safety issues with long-term treatment.

Key Insights